Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 5,60 € ( 266,01 %). Der Median liegt bei 5,60 € ( 266,01 %).
Kaufen |
2 |
Halten |
0
|
Verkaufen |
0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 5 / 18 |
Levermann-Strategie | -5 / 13 |
Beliebteste Broker
News
- 22.04. - 20:35 Uhr
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Preclinical data highlights the potential of engineered macrophage cell therapy as a treatment for liver and lung fibrosis Novel Redirected Soluble Modulator technology has demonstrated the potential to enhance immune receptor signaling PHILADELPHIA , April 22, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the acceptance of two abstracts at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting being held May 7-11, 2024, in Baltimore, MD. "We are excited to present new preclinical data highlighting the potential of our engineered macrophage cell therapies for the treatment of liver and lung fibrosis, both of which represent significant unmet medical needs with limited available therapies for patients," said Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer of Carisma. » Mehr auf prnewswire.com
- 04.04. - 14:56 Uhr
Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now
CARISMA THERAP (CARM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. » Mehr auf zacks.com
- 25.10. - 13:11 Uhr
Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023
-Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna -Two additional pre-clinical data abstracts highlighting next-generation enhancements to Carisma's cell therapy platform to be shared PHILADELPHIA , Oct. 25, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that new pre-clinical data leveraging an mRNA platform to develop in-vivo chimeric antigen receptor macrophage ("CAR-M") will be presented as a late-breaking abstract (#LBA1514) at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting held from Wednesday, November 1, to Sunday, November 5, 2023, in San Diego, California. Two posters highlighting next-generation enhancements to Carisma's CAR-M platform, including a custom intronic shRNA approach and data on Engineered Microenvironment Converters (EM-C), will also be presented. » Mehr auf prnewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Dez. 2023 | |
---|---|---|
Umsatz | 3,88 Mio | 11,55% |
Bruttoeinkommen | 1,99 Mio | 114,91% |
Nettoeinkommen | 18,96 Mio | 265,20% |
EBITDA | 18,42 Mio | 122,75% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 63,62 Mio € |
Anzahl Aktien | 41,54 Mio |
52 Wochen-Hoch/Tief | 9,12 € - 1,43 € |
Dividenden | Nein |
Beta | 0 |
KGV (PE Ratio) | 0,76 |
KGWV (PEG Ratio) | 0,03 |
KBV (PB Ratio) | 2,50 |
KUV (PS Ratio) | 4,57 |
Unternehmensprofil
Carisma Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das chimäre Antigenrezeptoren (CAR) Makrophagen für die Behandlung solider Tumore entwickelt. Die Lösungen von Carisma Therapeutics spielen eine entscheidende Rolle bei der angeborenen und adaptiven Immunantwort, und die Technologie nutzt die Fortschritte in der Makrophagenbiologie, der Entwicklung chimärer Antigenrezeptoren und der adoptiven Zelltherapie für die Behandlung menschlicher Krankheiten. Carisma Therapeutics, Inc. hat ein strategisches Kooperationsabkommen mit Moderna Inc. geschlossen. Carisma Therapeutics, Inc. war früher als CARMA Therapeutics Inc. bekannt und änderte im Mai 2017 seinen Namen in Carisma Therapeutics, Inc. um. Das Unternehmen wurde im Jahr 2016 gegründet und hat seinen Sitz in Philadelphia, Pennsylvania.
Name | CARISMA THERAPEUTICS INC |
CEO | Steven Kelly |
Sitz | Philadelphia,
pa USA |
Website | |
Industrie | Chemikalien |
Börsengang | 06.02.2014 |
Mitarbeiter | 107 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | CARM |
Frankfurt | W2J.F |
München | W2J.MU |
Hkse | 2858.HK |
Düsseldorf | W2J.DU |
Assets entdecken
Shareholder von CARISMA THERAPEUTICS INC investieren auch in folgende Assets